In continuation of my update on cancer drug development, I found this info interesting to share with. Researchers lead by Dr. Charles Kunos at the Ireland Cancer Center of University Hospitals (UH) have found that, Triapine, (3-aminopyridine-2-carbox -aldehyde thiosemicarbazone, see structure), which suppresses tumor growth shows a great deal of promise for cervical cancer patients who are at high risk for relapse and cancer-related death.
The phase I study found that the chemotherapy medicine Triapine, was well tolerated in combination with standard-of-care cisplatin chemotherapy and radiation treatment in women with cervical cancer. This regimen provided both significant reduction in cancer disease and cancer control.
In the study (ten-patient study) patients, were treated three times weekly with Triapine (a potent Ribonucleotide Reductase Inhibitor) in combination with weekly cisplatin treatment and daily pelvic radiation therapy over five weeks. The researchers claims that "a 100% complete response rate was observed and no disease progression was documented through 18 months of median follow-up."A phase two follow-up study is ongoing at the Ireland Cancer Center. UH Case Medical Center Hope this new found combintaton will be a promising new treatment to help women fight this aggressive disease in the days to come...
Ref : http://clincancerres.aacrjournals.org/content/16/4/1298.abstract?sid=f3df7c2d-9e46-4baf-b47b-83d310b87641
